REG-Biocompatibles Intl.: Directorate Change

.
31 July 2008

BIOCOMPATIBLES INTERNATIONAL PLC

("Biocompatibles" or the "Company")

Appointment of Dr. Anne Fairey as Non Executive Director

Farnham, UK, 31 July 2008: Biocompatibles (LSE:BII) is pleased to announce the
appointment of Anne Fairey, BM., FRCP., MFPM(Dis)., as a Non Executive Director
as of 1 September 2008.

Dr. Fairey has extensive medical and medical marketing experience working with
major pharmaceutical companies and has co-authored a number of publications.

Anne Fairey qualified as a doctor from Southampton University in 1985, and went
on to develop her medical career with Southampton General Hospital and the
Central Middlesex Hospital, specialising in Oncology. She then went into
industry focusing on clinical research in oncology with Sandoz Pharmaceuticals
which then became Novartis and then with Sanofi-Synthelabo. Latterly she
returned to Novartis as Medical Director.

Gerry Brown, Chairman, commented "I am delighted to welcome Anne to the Board
of Biocompatibles. Her extensive knowledge of medical and pharmaceutical
affairs, oncology and clinical research will enhance the leadership of
Biocompatibles and I very much look forward to working with her".

There is no information regarding Anne Fairey that is required to be disclosed
by LR 9.6.13.

-Ends-

Contact:

Biocompatibles
Crispin Simon, Chief Executive +44 (0)1252 732706
Ian Ardill, Finance Director

Biocompatibles International plc
Biocompatibles International plc is a leading medical technology company in the
field of drug device combination products, operating through three businesses.
The International Division conducts the marketing of Biocompatibles' approved
Bead products, which are sold to hospitals by our distribution partners,
including Angiodynamics Inc. and Terumo Corporation. The Drug Delivery and
CellMed businesses are engaged in new product development and licensing.

The Company's main programmes are Drug-Eluting Stents, licensed to Medtronic;
Cosmetic dermatology Beads licensed to Merz Pharmaceuticals; Drug-Eluting Bead
products for the treatment of cancer, by Endo-Vascular and Non-Vascular
delivery, which is unlicensed; and Drug-Eluting Beads for the treatment of
stroke, which is also unlicensed.

Further information is available at www.biocompatibles.com

END
nPRrVBEA9a